IL-15-based fusions to IL-12 and IL-18

Patent metadata

Field	Value
Publication number	US-11612645-B2
Application number	US-202217820980-A
Country	US
Kind code	B2
Filing date	Aug 19, 2022
Priority date	Mar 6, 2017
Publication date	Mar 28, 2023
Grant date	Mar 28, 2023

Abstract

The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-12 or IL-18.

First claim

What is claimed is:

1. An isolated soluble fusion protein complex comprising: a first soluble protein comprising an interleukin-15 (IL-15) polypeptide domain and a first cytokine binding polypeptide domain wherein the first cytokine binding polypeptide domain comprises a TGFβ receptor type 2 (TGFβRII), and a second soluble protein comprising, a soluble IL-15 receptor alpha sushi (IL-15RαSu) polypeptide domain and a second cytokine binding polypeptide domain wherein the second cytokine binding polypeptide domain comprises TGFβRII, wherein the IL-15 polypeptide domain binds to the IL-15RαtSu polypeptide domain to form the soluble fusion protein complex.

2. The soluble fusion protein complex of claim 1 , wherein the IL-15 polypeptide is an IL-15 variant comprising an N72D mutation (IL-15N72D).

3. The soluble fusion protein complex of claim 1 , wherein the cytokine binding polypeptide domains hind to TGFβ.

4. The soluble fusion protein complex of claim 1 , wherein the second soluble protein further comprises a biologically active polypeptide domain, and wherein the biologically active polypeptide domain comprises an immunoglobulin Fe polypeptide domain.

Assignees

• Altor Bioscience Llc

Inventors

• Marcus Warren D
• Newman Robert
• Liu Bai
• You Lijing
• Kong Lin
• Rhode Peter
• Wong Hing C

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C12N15/63

  Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title

• C07K14/7155

  for interleukins [IL] · CPC title

• C07K14/54

  Interleukins [IL] · CPC title

• C07K14/5443 Primary

  IL-15 · CPC title